Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

Published:2008-01-31 Issue:1 Volume:113 Page:95-100
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Coveler Andrew L.,Goodell Vivian,Webster Devon J.,Salazar Lupe G.,Fintak Patricia A.,Childs Jennifer S.,Higgins Doreen M.,Disis Mary L.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-008-9910-y.pdf

Reference27 articles.

1. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3(8):630–641

2. Disis ML, Shiota FM, Cheever MA (1998) Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ‘self’ tumour antigens. Immunology 93(2):192–199

3. Day RS, Shackney SE, Peters WP (2005) The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancer. Br J Cancer 92(1):47–54

4. Nicolini A, Carpi A, Rossi G (2006) Cytokines in breast cancer. Cytokine Growth Factor Rev 17(5):325–337

5. Disis ML, Gooley TA, Rinn K et al (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624–2632

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer;Clinical Cancer Research;2023-04-24

2. Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study;Clinical Cancer Research;2019-01-11

3. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines;Breast Cancer Research and Treatment;2013-01-23

4. Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response;Cancer Research;2010-12-14

5. Targeting the Immune System as a Therapeutic Strategy for Patients with Breast Cancer;Current Breast Cancer Reports;2010-10-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3